Heike Woehling

Learn More
OBJECTIVE To evaluate the efficacy of oral treatment with nebivolol and metoprolol in the prophylaxis of migraine attacks. BACKGROUND Beta-blockers such as propranolol and metoprolol are known to be effective in preventing migraine attacks. Following earlier observations of successful use of nebivolol in a few hypertensive patients with concomitant(More)
BACKGROUND GP2015 is a proposed etanercept biosimilar. OBJECTIVES To demonstrate equivalent efficacy, and comparable safety and immunogenicity of GP2015 and the etanercept originator (ETN, Enbrel® ) in patients with moderate-to-severe chronic plaque-type psoriasis. METHODS In total, 531 eligible patients were randomized 1 : 1 to self-administer GP2015(More)
Introduction: A new treatment plan was implemented at Skåne University Hospital, on economic grounds, for children requiring recombinant human growth hormone (rhGH) treatment. This involved switching patients from treatment with originator rhGHs to treatment with a biosimilar rhGH, somatropin (Omnitrope ), using a Dialogue Teamwork approach. The feasibility(More)
INTRODUCTION This study was conducted using an integrated retrospective database to evaluate the effectiveness of Omnitrope(®) (Sandoz) on children with growth hormone deficiency (GHD), idiopathic short stature (ISS), and Turner Syndrome (TS) who switched from a non-Omnitrope recombinant human growth hormone (rhGH) preparation during routine clinical care.(More)
INTRODUCTION This ongoing, prospective, open-label, non-comparative, multicenter phase IV study is evaluating the safety and efficacy of recombinant human growth hormone (rhGH; Omnitrope(®), Sandoz GmbH) in short children born small for gestational age (SGA). Here we report data from patients who have completed 2 years' treatment. METHODS Eligibility(More)
AIM National European growth references differ. We aimed to convert (harmonize) currently used charts into a single unified interchangeable LMS format for each European nation. METHODS Nine currently used national European growth references from Belgium (2009), France (1979), Poland (2001), Sweden (2002), Switzerland (1989), the UK (1990), Italy (2006)(More)
BACKGROUND EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque-type psoriasis as a part of totality of evidence gathered during the development of GP2015, an etanercept biosimilar. OBJECTIVE To demonstrate equivalent efficacy and comparable safety and immunogenicity of GP2015 and the etanercept originator(More)
The authors of the above-mentioned paper noticed some errors subsequent to publication and would like to make the following corrections. On pages 5 and 6, Table 1 will include a footnote for the prior non-Omnitrope rhGH therapy: ‘‘These patients are not mutually exclusive, they could have been on multiple GH therapies prior to switching to Omnitrope’’. On(More)
Paresthesia and other malfunction of sense are typical complaints of peripheral neuropathy (PNP) which are most often located symmetrically in the lower limbs. In more severe forms, there are also paresis, muscular atrophy and trophical changes of the skin. The prevalence of PNP is estimated at 1:2500 inhabitants in Germany. Etiologic relations include(More)
  • 1